首页 > 最新文献

Clinical Parkinsonism Related Disorders最新文献

英文 中文
Validation of the Kazakh version of the movement disorder Society-Unified Parkinson's disease rating scale 运动障碍协会统一帕金森病评分量表哈萨克斯坦版的验证
Q3 CLINICAL NEUROLOGY Pub Date : 2024-01-01 DOI: 10.1016/j.prdoa.2024.100232
Saltanat Abdraimova , Zhanybek Myrzayev , Altynay Karimova , Altynay Talgatkyzy , Talgat Khaibullin , Gulnaz Kaishibayeva , Sandugash Elubaeva , Karlygash Esembekova , Dongrak Choi , Pablo Martinez-Martin , Christopher G. Goetz , Glenn T. Stebbins , Sheng Luo , Chingiz Shashkin , Nazira Zharkinbekova , Rauan Kaiyrzhanov

Background and Purpose

The International Movement Disorder Society revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) is widely used in the assessment of the severity of Parkinson’s disease (PD). This study aimed to validate the Kazakh version of the MDS-UPDRS, explore its dimensionality, and compare it to the original English version.

Methods

The validation was conducted in three phases: first, the English version of the MDS-UPDRS was translated into Kazakh and thereafter back-translated into English by two independent teams; second, the Kazakh version underwent a cognitive pretesting; third, the Kazakh version was tested in 360 native Kazakh-speaking PD patients. Both confirmatory and exploratory factor analyses were performed to validate the scale. We calculated the comparative fit index (CFI) for confirmatory factor analysis and used unweighted least squares for exploratory factor analysis.

Results

The CFI was higher than 0.90 for all parts of the scale, thereby meeting the pre-set threshold for the official designation of a validated translation. Exploratory factor analysis also showed that the Kazakh MDS-UPDRS has the analogous factors structure in each part as the English version.

Conclusions

The Kazakh MDS-UPDRS had a consistent overall structure as the English MDS-UPDRS, and it was designated as the official Kazakh MDS-UPDRS, which can reliably be used in the Kazakh-speaking populations. Presently, Kazakhstan stands as the sole country in both Central Asia and Transcaucasia with an MDS-approved translated version of the MDS-UPDRS. We expect that other Central Asian and Transcaucasian countries will embark on the MDS Translation Program for MDS-UPDRS in the near future.

背景和目的国际运动障碍协会修订的统一帕金森病评分量表(MDS-UPDRS)被广泛用于评估帕金森病(PD)的严重程度。本研究旨在验证哈萨克语版的MDS-UPDRS,探索其维度,并将其与原始英语版进行比较。方法验证分三个阶段进行:首先,由两个独立团队将英语版的MDS-UPDRS翻译成哈萨克语,然后再反译成英语;其次,对哈萨克语版进行认知预试;第三,在360名以哈萨克语为母语的帕金森病患者中对哈萨克语版进行测试。为了验证量表,我们进行了确认性和探索性因素分析。我们计算了确认性因子分析的比较拟合指数(CFI),并使用非加权最小二乘法进行了探索性因子分析。结果量表所有部分的CFI均高于0.90,因此达到了官方指定的验证翻译的预设阈值。结论哈萨克语 MDS-UPDRS 与英语 MDS-UPDRS 具有一致的整体结构,因此被指定为官方哈萨克语 MDS-UPDRS,可在哈萨克语人群中可靠使用。目前,哈萨克斯坦是中亚和外高加索地区唯一拥有经 MDS 批准的 MDS-UPDRS 翻译版本的国家。我们希望其他中亚和外高加索国家也能在不久的将来启动 MDS-UPDRS 的 MDS 翻译计划。
{"title":"Validation of the Kazakh version of the movement disorder Society-Unified Parkinson's disease rating scale","authors":"Saltanat Abdraimova ,&nbsp;Zhanybek Myrzayev ,&nbsp;Altynay Karimova ,&nbsp;Altynay Talgatkyzy ,&nbsp;Talgat Khaibullin ,&nbsp;Gulnaz Kaishibayeva ,&nbsp;Sandugash Elubaeva ,&nbsp;Karlygash Esembekova ,&nbsp;Dongrak Choi ,&nbsp;Pablo Martinez-Martin ,&nbsp;Christopher G. Goetz ,&nbsp;Glenn T. Stebbins ,&nbsp;Sheng Luo ,&nbsp;Chingiz Shashkin ,&nbsp;Nazira Zharkinbekova ,&nbsp;Rauan Kaiyrzhanov","doi":"10.1016/j.prdoa.2024.100232","DOIUrl":"10.1016/j.prdoa.2024.100232","url":null,"abstract":"<div><h3>Background and Purpose</h3><p>The International Movement Disorder Society revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) is widely used in the assessment of the severity of Parkinson’s disease (PD). This study aimed to validate the Kazakh version of the MDS-UPDRS, explore its dimensionality, and compare it to the original English version.</p></div><div><h3>Methods</h3><p>The validation was conducted in three phases: first, the English version of the MDS-UPDRS was translated into Kazakh and thereafter back-translated into English by two independent teams; second, the Kazakh version underwent a cognitive pretesting; third, the Kazakh version was tested in 360 native Kazakh-speaking PD patients. Both confirmatory and exploratory factor analyses were performed to validate the scale. We calculated the comparative fit index (CFI) for confirmatory factor analysis and used unweighted least squares for exploratory factor analysis.</p></div><div><h3>Results</h3><p>The CFI was higher than 0.90 for all parts of the scale, thereby meeting the pre-set threshold for the official designation of a validated translation. Exploratory factor analysis also showed that the Kazakh MDS-UPDRS has the analogous factors structure in each part as the English version.</p></div><div><h3>Conclusions</h3><p>The Kazakh MDS-UPDRS had a consistent overall structure as the English MDS-UPDRS, and it was designated as the official Kazakh MDS-UPDRS, which can reliably be used in the Kazakh-speaking populations. Presently, Kazakhstan stands as the sole country in both Central Asia and Transcaucasia with an MDS-approved translated version of the MDS-UPDRS. We expect that other Central Asian and Transcaucasian countries will embark on the MDS Translation Program for MDS-UPDRS in the near future.</p></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"10 ","pages":"Article 100232"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S259011252400001X/pdfft?md5=7507318bbf0ae4d7de353871d67c1485&pid=1-s2.0-S259011252400001X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139396136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Valosin-containing-protein pathogenic variant p.R487H in Parkinson’s disease 帕金森病中的含缬氨苷蛋白致病变体 p.R487H
Q3 CLINICAL NEUROLOGY Pub Date : 2024-01-01 DOI: 10.1016/j.prdoa.2024.100236
Capucine Piat, Owen A. Ross, Wolfdieter Springer, Eduardo E. Benarroch, J. Layne Moore, Emily Lauer, Zhiyv Niu, Rodolfo Savica

We describe a 66-year-old woman with Parkinson’s disease, carrying a known pathogenic missense variant in the Valosin-containing-protein (VCP) gene. She responded excellently to L-dopa, had no cognitive or motoneuronal dysfunction. Laboratory analyses and MRI were unremarkable. Genetic testing revealed a heterozygous variant in VCP(NM_007126.5), chr9 (GRCh3 7):g.35060820C > T, c.1460G > A p.Arg487His (p.R487H).

我们描述了一名患有帕金森病的 66 岁女性患者,她的缬氨酸含蛋白(VCP)基因携带一个已知的致病性错义变体。她对左旋多巴反应良好,没有认知或运动神经元功能障碍。实验室分析和核磁共振成像均无异常。基因检测显示,她的 VCP(NM_007126.5) chr9 (GRCh3 7) 基因存在杂合变异:g.35060820C > T, c.1460G > A p.Arg487His (p.R487H)。
{"title":"Valosin-containing-protein pathogenic variant p.R487H in Parkinson’s disease","authors":"Capucine Piat,&nbsp;Owen A. Ross,&nbsp;Wolfdieter Springer,&nbsp;Eduardo E. Benarroch,&nbsp;J. Layne Moore,&nbsp;Emily Lauer,&nbsp;Zhiyv Niu,&nbsp;Rodolfo Savica","doi":"10.1016/j.prdoa.2024.100236","DOIUrl":"https://doi.org/10.1016/j.prdoa.2024.100236","url":null,"abstract":"<div><p>We describe a 66-year-old woman with Parkinson’s disease, carrying a known pathogenic missense variant in the Valosin-containing-protein (<em>VCP</em>) gene. She responded excellently to L-dopa, had no cognitive or motoneuronal dysfunction. Laboratory analyses and MRI were unremarkable. Genetic testing revealed a heterozygous variant in <em>VCP</em>(NM_007126.5), chr9 (GRCh3 7):g.35060820C &gt; T, c.1460G &gt; A p.Arg487His (p.R487H).</p></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"10 ","pages":"Article 100236"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590112524000057/pdfft?md5=e55fd004326e5eadac7a281cd165485b&pid=1-s2.0-S2590112524000057-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139549345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mucuna beans administered through hydrogen-infused superheated steam in advanced Parkinson's disease 通过注入氢气的过热蒸汽给晚期帕金森病患者服用木瓜豆
Q3 CLINICAL NEUROLOGY Pub Date : 2024-01-01 DOI: 10.1016/j.prdoa.2024.100252
Ryuji Neshige, Shuichiro Neshige

This retrospective review on patients with Parkinson's disease, focusing on using mucuna beans (MB), its dosing, and administration methods. Two hundred patients taking 1–3 g of MP dissolved in hot water daily orally. Besides, MB administration via enema may be viable, especially when oral L-dopa efficacy is insufficient.

本研究对帕金森病患者进行了回顾性研究,重点关注粘金枪鱼豆(MB)的使用、剂量和给药方法。200 名患者每天口服 1-3 克溶于热水的粘金枪鱼豆。此外,通过灌肠给药也是可行的,尤其是在口服左旋多巴疗效不佳时。
{"title":"Mucuna beans administered through hydrogen-infused superheated steam in advanced Parkinson's disease","authors":"Ryuji Neshige,&nbsp;Shuichiro Neshige","doi":"10.1016/j.prdoa.2024.100252","DOIUrl":"https://doi.org/10.1016/j.prdoa.2024.100252","url":null,"abstract":"<div><p>This retrospective review on patients with Parkinson's disease, focusing on using mucuna beans (MB), its dosing, and administration methods. Two hundred patients taking 1–3 g of MP dissolved in hot water daily orally. Besides, MB administration via enema may be viable, especially when oral L-dopa efficacy is insufficient.</p></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"10 ","pages":"Article 100252"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590112524000239/pdfft?md5=97b83fa446a45b1c199dc1390659ce2b&pid=1-s2.0-S2590112524000239-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140551590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Progressive supranuclear palsy phenotype as an atypical clinical presentation of Creutzfeldt-Jakob disease: A case report and review of the literature 作为克雅氏病非典型临床表现的进行性核上性麻痹表型:病例报告和文献综述
Q3 CLINICAL NEUROLOGY Pub Date : 2024-01-01 DOI: 10.1016/j.prdoa.2024.100247
Matteo Costanzo , Flavia Aiello , Anna Poleggi , Pietro Li Voti , Giovanni Fabbrini , Daniele Belvisi

Creutzfeldt-Jakob disease (CJD) is a rare, rapidly progressive neurodegenerative disorder, characterized by the accumulation of abnormal prion proteins in the brain. While CJD has some typical clinical features, its presentation can be quite heterogeneous, particularly in the early stages of the disease, posing challenges in diagnosis. Atypical manifestations of CJD can mimic various neurodegenerative disorders, including atypical parkinsonisms. In this case report, we present an 81-year-old man who exhibited an atypical clinical presentation of sporadic CJD, initially resembling progressive supranuclear palsy (PSP). The patient presented with symmetric parkinsonism, postural instability, and ocular motor dysfunction, accompanied by rapid clinical deterioration. Alongside the case report, we also provide a review of the literature on atypical presentations of CJD as PSP, highlighting the importance of recognizing these manifestations in clinical practice.

克雅氏病(CJD)是一种罕见的快速进展性神经退行性疾病,其特征是大脑中异常朊蛋白的积累。虽然 CJD 有一些典型的临床特征,但其表现可能相当多样,尤其是在疾病的早期阶段,这给诊断带来了挑战。CJD 的非典型表现可模拟各种神经退行性疾病,包括非典型帕金森病。在本病例报告中,我们介绍了一名 81 岁的男性患者,他表现出散发性 CJD 的非典型临床表现,最初类似于进行性核上性麻痹(PSP)。患者表现为对称性帕金森病、姿势不稳和眼球运动功能障碍,并伴有快速的临床恶化。在报告病例的同时,我们还回顾了有关 CJD 不典型表现为 PSP 的文献,强调了在临床实践中识别这些表现的重要性。
{"title":"Progressive supranuclear palsy phenotype as an atypical clinical presentation of Creutzfeldt-Jakob disease: A case report and review of the literature","authors":"Matteo Costanzo ,&nbsp;Flavia Aiello ,&nbsp;Anna Poleggi ,&nbsp;Pietro Li Voti ,&nbsp;Giovanni Fabbrini ,&nbsp;Daniele Belvisi","doi":"10.1016/j.prdoa.2024.100247","DOIUrl":"https://doi.org/10.1016/j.prdoa.2024.100247","url":null,"abstract":"<div><p>Creutzfeldt-Jakob disease (CJD) is a rare, rapidly progressive neurodegenerative disorder, characterized by the accumulation of abnormal prion proteins in the brain. While CJD has some typical clinical features, its presentation can be quite heterogeneous, particularly in the early stages of the disease, posing challenges in diagnosis. Atypical manifestations of CJD can mimic various neurodegenerative disorders, including atypical parkinsonisms. In this case report, we present an 81-year-old man who exhibited an atypical clinical presentation of sporadic CJD, initially resembling progressive supranuclear palsy (PSP). The patient presented with symmetric parkinsonism, postural instability, and ocular motor dysfunction, accompanied by rapid clinical deterioration. Alongside the case report, we also provide a review of the literature on atypical presentations of CJD as PSP, highlighting the importance of recognizing these manifestations in clinical practice.</p></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"10 ","pages":"Article 100247"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590112524000161/pdfft?md5=2accb256acc98b4f2c4ae1f5e4c832a5&pid=1-s2.0-S2590112524000161-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140051641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The potential role of chronic pain and the polytrauma clinical triad in predicting prodromal PD: A cross-sectional study of U.S. Veterans 慢性疼痛和多发性创伤临床三联征在预测前驱性帕金森病中的潜在作用:对美国退伍军人的横断面研究
Q3 CLINICAL NEUROLOGY Pub Date : 2024-01-01 DOI: 10.1016/j.prdoa.2024.100253
Lee E. Neilson , Nadir M. Balba , Jonathan E. Elliott , Gregory D. Scott , Scott D. Mist , Matthew P. Butler , Mary M. Heinricher , Miranda M. Lim

Introduction

The research criteria for prodromal Parkinson disease (pPD) depends on prospectively validated clinical inputs with large effect sizes and/or high prevalence. Neither traumatic brain injury (TBI), post-traumatic stress disorder (PTSD), nor chronic pain are currently included in the calculator, despite recent evidence of association with pPD. These conditions are widely prevalent, co-occurring, and already known to confer risk of REM behavior disorder (RBD) and PD. Few studies have examined PD risk in the context of TBI and PTSD; none have examined chronic pain. This study aimed to measure the risk of pPD caused by TBI, PTSD, and chronic pain.

Methods

216 US Veterans were enrolled who had self-reported recurrent or persistent pain for at least three months. Of these, 44 met criteria for PTSD, 39 for TBI, and 41 for all three conditions. Several pain, sleep, affective, and trauma questionnaires were administered. Participants’ history of RBD was determined via self-report, with a subset undergoing confirmatory video polysomnography.

Results

A greater proportion of Veterans with chronic pain met criteria for RBD (36 % vs. 10 %) and pPD (18.0 % vs. 8.3 %) compared to controls. Proportions were increased in RBD (70 %) and pPD (27 %) when chronic pain co-occurred with TBI and PTSD. Partial effects were seen with just TBI or PTSD alone. When analyzed as continuous variables, polytrauma symptom severity correlated with pPD probability (r = 0.28, P = 0.03).

Conclusion

These data demonstrate the potential utility of chronic pain, TBI, and PTSD in the prediction of pPD, and the importance of trauma-related factors in the pathogenesis of PD.

导言帕金森病前驱期(pPD)的研究标准取决于经前瞻性验证的、具有大效应量和/或高患病率的临床输入。尽管最近有证据表明创伤性脑损伤(TBI)、创伤后应激障碍(PTSD)和慢性疼痛与帕金森病有关联,但它们目前均未被纳入计算器。这些疾病广泛流行,同时存在,而且已知会带来快速眼动行为障碍(RBD)和肢端麻痹症的风险。很少有研究对创伤后应激障碍(TBI)和创伤后应激障碍(PTSD)情况下的帕金森病风险进行研究,也没有研究对慢性疼痛进行研究。本研究旨在测量由创伤后应激障碍、创伤后应激障碍和慢性疼痛引起的急性肢体功能障碍的风险。研究方法216名美国退伍军人参加了研究,他们自述有至少三个月的复发性或持续性疼痛。其中 44 人符合创伤后应激障碍的标准,39 人符合创伤后应激障碍的标准,41 人符合所有三种情况的标准。他们接受了多项疼痛、睡眠、情感和创伤问卷调查。结果与对照组相比,患有慢性疼痛的退伍军人中符合 RBD(36% 对 10%)和 PPD(18.0% 对 8.3%)标准的比例更高。当慢性疼痛同时伴有创伤后应激障碍和创伤后应激障碍时,RBD(70%)和pPD(27%)的比例会增加。仅有创伤性脑损伤或创伤后应激障碍会产生部分影响。这些数据表明,慢性疼痛、创伤后应激障碍和创伤后应激障碍在预测创伤后应激障碍中的潜在作用,以及创伤相关因素在创伤后应激障碍发病机制中的重要性。
{"title":"The potential role of chronic pain and the polytrauma clinical triad in predicting prodromal PD: A cross-sectional study of U.S. Veterans","authors":"Lee E. Neilson ,&nbsp;Nadir M. Balba ,&nbsp;Jonathan E. Elliott ,&nbsp;Gregory D. Scott ,&nbsp;Scott D. Mist ,&nbsp;Matthew P. Butler ,&nbsp;Mary M. Heinricher ,&nbsp;Miranda M. Lim","doi":"10.1016/j.prdoa.2024.100253","DOIUrl":"https://doi.org/10.1016/j.prdoa.2024.100253","url":null,"abstract":"<div><h3>Introduction</h3><p>The research criteria for prodromal Parkinson disease (pPD) depends on prospectively validated clinical inputs with large effect sizes and/or high prevalence. Neither traumatic brain injury (TBI), post-traumatic stress disorder (PTSD), nor chronic pain are currently included in the calculator, despite recent evidence of association with pPD. These conditions are widely prevalent, co-occurring, and already known to confer risk of REM behavior disorder (RBD) and PD. Few studies have examined PD risk in the context of TBI and PTSD; none have examined chronic pain. This study aimed to measure the risk of pPD caused by TBI, PTSD, and chronic pain.</p></div><div><h3>Methods</h3><p>216 US Veterans were enrolled who had self-reported recurrent or persistent pain for at least three months. Of these, 44 met criteria for PTSD, 39 for TBI, and 41 for all three conditions. Several pain, sleep, affective, and trauma questionnaires were administered. Participants’ history of RBD was determined via self-report, with a subset undergoing confirmatory video polysomnography.</p></div><div><h3>Results</h3><p>A greater proportion of Veterans with chronic pain met criteria for RBD (36 % vs. 10 %) and pPD (18.0 % vs. 8.3 %) compared to controls. Proportions were increased in RBD (70 %) and pPD (27 %) when chronic pain co-occurred with TBI and PTSD. Partial effects were seen with just TBI or PTSD alone. When analyzed as continuous variables, polytrauma symptom severity correlated with pPD probability (r = 0.28, <em>P</em> = 0.03).</p></div><div><h3>Conclusion</h3><p>These data demonstrate the potential utility of chronic pain, TBI, and PTSD in the prediction of pPD, and the importance of trauma-related factors in the pathogenesis of PD.</p></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"10 ","pages":"Article 100253"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590112524000240/pdfft?md5=1782dc09624054d86644af86f9ee1983&pid=1-s2.0-S2590112524000240-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140641122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Movement disorder Deep brain stimulation Hybridization: Patient and caregiver outcomes 运动障碍深部脑刺激杂交:患者和护理人员的成果
Q3 CLINICAL NEUROLOGY Pub Date : 2024-01-01 DOI: 10.1016/j.prdoa.2024.100234
Nathan Esplin, Dorian Kusyk, Seung W Jeong, Shahed Elhamdani, Khaled Abdel Aziz, Amanda Webb, Cindy Angle, Donald Whiting, Nestor D. Tomycz

Background and Objectives

Deep brain stimulation (DBS) is a well-established surgical treatment for certain movement disorders and involves the implantation of brain electrodes connected to implantable pulse generators (IPGs). As more device manufacturers have entered the market, some IPG technology has been designed to be compatible with brain electrodes from other manufacturers, which has facilitated the hybridization of implant technology. The aim of this study was to assess the benefits of hybridization of non-rechargeable, constant voltage IPGs to rechargeable, constant current IPGs.

Methods

A list of DBS movement disorder patients who had their non-rechargeable, constant voltage IPGs replaced with rechargeable, constant current IPGs from a different manufacturer was compiled. Structured surveys of these patients, and their caregivers when applicable, were undertaken to determine both patient and caregiver satisfaction in this DBS hybridization strategy.

Results

Eighteen patients met inclusion criteria and twelve patients or their caregivers completed the structured survey (67% response rate). Nine patients had Parkinson’s disease (75%), three had essential tremor (25%). Nine (75%) were converted from bilateral single-channel IPGs, and three (25%) were converted from a unilateral dual-channel IPGs. Overall, 92% of patients and caregivers surveyed reported improvement or no change in their symptoms, 92% reported a decrease or no change in their medication requirements, and 92% report they are satisfied or very satisfied with their IPG hybridization and would recommend the surgery to similar patients. There were no immediate surgical complications.

Conclusion

In this series of movement disorder DBS patients, surgery was safe and patient and caregiver satisfaction were high with a hybridization of non-rechargeable, constant voltage IPGs to rechargeable, constant current IPGs.

背景和目的脑深部刺激(DBS)是一种治疗某些运动障碍的成熟手术疗法,包括植入与植入式脉冲发生器(IPG)相连的脑电极。随着越来越多的设备制造商进入市场,一些 IPG 技术被设计成与其他制造商的脑电极兼容,这促进了植入技术的杂交。本研究的目的是评估非充电式恒压 IPG 与充电式恒流 IPG 混合植入的益处。方法编制了一份 DBS 运动障碍患者名单,这些患者的非充电式恒压 IPG 已被不同制造商生产的充电式恒流 IPG 所取代。结果 18 名患者符合纳入标准,12 名患者或其护理人员完成了结构化调查(回复率为 67%)。九名患者患有帕金森病(75%),三名患者患有本质性震颤(25%)。九名患者(75%)由双侧单通道 IPG 转换而来,三名患者(25%)由单侧双通道 IPG 转换而来。总体而言,92% 的受访患者和护理人员表示症状有所改善或无变化,92% 的受访者表示药物需求有所减少或无变化,92% 的受访者表示对 IPG 杂交手术感到满意或非常满意,并会向类似患者推荐该手术。结论 在这一系列运动障碍 DBS 患者中,将非充电式恒压 IPG 与充电式恒流 IPG 杂交的手术是安全的,患者和护理人员的满意度很高。
{"title":"Movement disorder Deep brain stimulation Hybridization: Patient and caregiver outcomes","authors":"Nathan Esplin,&nbsp;Dorian Kusyk,&nbsp;Seung W Jeong,&nbsp;Shahed Elhamdani,&nbsp;Khaled Abdel Aziz,&nbsp;Amanda Webb,&nbsp;Cindy Angle,&nbsp;Donald Whiting,&nbsp;Nestor D. Tomycz","doi":"10.1016/j.prdoa.2024.100234","DOIUrl":"10.1016/j.prdoa.2024.100234","url":null,"abstract":"<div><h3>Background and Objectives</h3><p>Deep brain stimulation (DBS) is a well-established surgical treatment for certain movement disorders and involves the implantation of brain electrodes connected to implantable pulse generators (IPGs). As more device manufacturers have entered the market, some IPG technology has been designed to be compatible with brain electrodes from other manufacturers, which has facilitated the hybridization of implant technology. The aim of this study was to assess the benefits of hybridization of non-rechargeable, constant voltage IPGs to rechargeable, constant current IPGs.</p></div><div><h3>Methods</h3><p>A list of DBS movement disorder patients who had their non-rechargeable, constant voltage IPGs replaced with rechargeable, constant current IPGs from a different manufacturer was compiled. Structured surveys of these patients, and their caregivers when applicable, were undertaken to determine both patient and caregiver satisfaction in this DBS hybridization strategy.</p></div><div><h3>Results</h3><p>Eighteen patients met inclusion criteria and twelve patients or their caregivers completed the structured survey (67% response rate). Nine patients had Parkinson’s disease (75%), three had essential tremor (25%). Nine (75%) were converted from bilateral single-channel IPGs, and three (25%) were converted from a unilateral dual-channel IPGs. Overall, 92% of patients and caregivers surveyed reported improvement or no change in their symptoms, 92% reported a decrease or no change in their medication requirements, and 92% report they are satisfied or very satisfied with their IPG hybridization and would recommend the surgery to similar patients. There were no immediate surgical complications.</p></div><div><h3>Conclusion</h3><p>In this series of movement disorder DBS patients, surgery was safe and patient and caregiver satisfaction were high with a hybridization of non-rechargeable, constant voltage IPGs to rechargeable, constant current IPGs.</p></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"10 ","pages":"Article 100234"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590112524000033/pdfft?md5=43a1929caa2886be8101445aa9f2f19a&pid=1-s2.0-S2590112524000033-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139396170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The selfie sign in the diagnosis of functional tremor 功能性震颤诊断中的自拍体征
Q3 CLINICAL NEUROLOGY Pub Date : 2024-01-01 DOI: 10.1016/j.prdoa.2024.100238
Ekhlas Assaedi, Xin Xin Yu, Junaid Siddiqui, Umar A Shuaib

Functional tremor (FT) is the most common phenotype of functional movement disorders (FMD). Its diagnosis can often be challenging. While positive signs such as tremor variability, distractibility, and entrainment support a diagnosis of FT, these diagnostic clues may not always be present and can be challenging to assess. In this case series, we identify another examination technique which could be of value when assessing FT. In our Movement Disorders clinic, charts were retrospectively reviewed for relevant clinical information. Video examinations were conducted. Obtained videos were either synchronous, via the use of screen recording software during telehealth visits or asynchronous, from self-recorded home videos. In both settings, patients were instructed to self-record their tremor using their phone cameras. Three patients with FT or comorbid FT were identified as demonstrating a unique examination sign. Videos showed an improvement or suppression of the tremor when the phone was held by the affected hand. When compared to a patient with tremor-dominant Parkinson’s disease serving as a control, this “selfie sign” was not observed. These observations are preliminary and larger studies are needed to confirm the usefulness of the selfie sign in diagnosing FT. Patient-recorded videos of their tremor can be a convenient and practical way of evaluating suspected FT, especially when paroxysmal or variable symptoms limit the usefulness of classic signs often assessed in the clinic.

功能性震颤(FT)是功能性运动障碍(FMD)最常见的表型。其诊断往往具有挑战性。虽然震颤变异性、注意力分散和夹带等阳性体征支持功能性震颤的诊断,但这些诊断线索并不总是存在,而且评估起来也很困难。在本系列病例中,我们发现了另一种在评估 FT 时可能有价值的检查技术。在我们的运动障碍门诊中,我们回顾性地查看了病历中的相关临床信息。我们还进行了视频检查。获得的视频可以是同步视频,即在远程医疗就诊时使用屏幕录制软件;也可以是异步视频,即患者自行录制的家庭视频。在这两种情况下,患者都被要求使用手机摄像头自行记录震颤情况。三名患有震颤或合并震颤的患者被确认为表现出独特的检查体征。视频显示,当受影响的手握住手机时,震颤有所改善或抑制。与作为对照的震颤为主的帕金森病患者相比,没有观察到这种 "自拍征兆"。这些观察结果只是初步的,还需要更大规模的研究来证实自拍手势在诊断 FT 中的作用。患者录制的震颤视频是评估疑似 FT 的一种方便实用的方法,尤其是当阵发性或多变的症状限制了临床上经常评估的经典体征的作用时。
{"title":"The selfie sign in the diagnosis of functional tremor","authors":"Ekhlas Assaedi,&nbsp;Xin Xin Yu,&nbsp;Junaid Siddiqui,&nbsp;Umar A Shuaib","doi":"10.1016/j.prdoa.2024.100238","DOIUrl":"https://doi.org/10.1016/j.prdoa.2024.100238","url":null,"abstract":"<div><p>Functional tremor (FT) is the most common phenotype of functional movement disorders (FMD). Its diagnosis can often be challenging. While positive signs such as tremor variability, distractibility, and entrainment support a diagnosis of FT, these diagnostic clues may not always be present and can be challenging to assess. In this case series, we identify another examination technique which could be of value when assessing FT. In our Movement Disorders clinic, charts were retrospectively reviewed for relevant clinical information. Video examinations were conducted. Obtained videos were either synchronous, via the use of screen recording software during telehealth visits or asynchronous, from self-recorded home videos. In both settings, patients were instructed to self-record their tremor using their phone cameras. Three patients with FT or comorbid FT were identified as demonstrating a unique examination sign. Videos showed an improvement or suppression of the tremor when the phone was held by the affected hand. When compared to a patient with tremor-dominant Parkinson’s disease serving as a control, this “selfie sign” was not observed. These observations are preliminary and larger studies are needed to confirm the usefulness of the selfie sign in diagnosing FT. Patient-recorded videos of their tremor can be a convenient and practical way of evaluating suspected FT, especially when paroxysmal or variable symptoms limit the usefulness of classic signs often assessed in the clinic.</p></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"10 ","pages":"Article 100238"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590112524000070/pdfft?md5=6fbc27f7840c736a21debe86e769a9ff&pid=1-s2.0-S2590112524000070-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139653837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring the layers of fatigue in Parkinson’s Disease: A comprehensive analysis of its prevalence and contributing factors 探索帕金森病疲劳的层次:全面分析帕金森病的发病率和诱因
IF 1.9 Q3 CLINICAL NEUROLOGY Pub Date : 2024-01-01 DOI: 10.1016/j.prdoa.2024.100288
Filipe Sarmento , Griffin Lamp , Venkat Srikar Lavu , Achyutha S. Madamangalam , Jagan Mohan Reddy Dwarampudi , Qingqi Yuan , Alfonso Enrique Martinez-Nunez , Julia Choi , Kara A. Johnson , Coralie de Hemptinne , Joshua K. Wong

Background

Fatigue is a prevalent yet under-recognized non-motor symptom (NMS) of Parkinson’s disease (PD), significantly impacting patients’ quality of life. Despite its clinical importance, the relationship between fatigue and other motor and non-motor symptoms remains poorly understood. Its frequent co-occurrence with other NMS further complicates both diagnosis and management, often leading to underdiagnosis and suboptimal treatment. This gap in understanding is largely due to the limited exploration of fatigue in PD.

Objective

This study aimed to evaluate the prevalence of fatigue at baseline and up to 10 years after symptom onset in a large, well-characterized PD cohort (PPMI) and to explore its associations with other non-motor symptoms (NMS). By providing insights into the prevalence and correlations of fatigue, our goal is to highlight the need for early identification and management, guiding future research efforts.

Methods

 We conducted a retrospective study using the PPMI database. Fatigue was assessed using item 1.13 of the Movement Disorders Society Unified Parkinson’s Disease Rating Scale. Logistic regression was used to analyze the impact of different variables on fatigue, while point-biserial correlation analysis gauged the relationship between continuous variables and fatigue.

Results

At baseline study visit, 52% (575) of patients reported experiencing fatigue, with 9% reporting moderate to severe fatigue early in the disease course. Higher scores on several scales were significantly associated with an increased risk of fatigue, though most associations were weak. Significant associations included the REM Sleep Behavioral Disorder Questionnaire (OR: 1.09, 95% CI: 1.06–1.11), Geriatric Depression Scale (OR: 1.07, 95% CI: 1.03–1.11), State-Trait Anxiety Inventory (OR: 1.01, 95% CI: 1.00–1.02), SCOPA-Autonomic Dysfunction (OR: 1.05, 95% CI: 1.03–1.06), Epworth Sleepiness Scale (OR: 1.06, 95% CI: 1.04–1.08), and Apathy (OR: 2.90, 95% CI: 2.4–3.5).

Conclusion

Over half of patients reported fatigue at baseline, underscoring its significant prevalence early in PD. The predominantly weak associations with other NMS highlight the necessity for comprehensive patient screening and targeted interventions, as addressing one NMS may not effectively alleviate others.
背景疲劳是帕金森病(PD)的一种普遍但未得到充分认识的非运动症状(NMS),严重影响患者的生活质量。尽管疲劳具有重要的临床意义,但人们对疲劳与其他运动症状和非运动症状之间的关系仍然知之甚少。疲劳经常与其他非运动症状同时出现,使诊断和治疗更加复杂,往往导致诊断不足和治疗效果不佳。本研究旨在评估一个大型、特征明确的帕金森病队列(PPMI)中基线和症状发作后长达 10 年的疲劳患病率,并探讨其与其他非运动症状(NMS)的关联。通过深入了解疲劳的患病率和相关性,我们的目标是强调早期识别和管理的必要性,为未来的研究工作提供指导。我们利用 PPMI 数据库进行了一项回顾性研究,采用运动障碍协会帕金森病统一评分量表的第 1.13 项对疲劳进行评估。采用逻辑回归分析了不同变量对疲劳的影响,而点-阶梯相关分析则衡量了连续变量与疲劳之间的关系。 结果在基线研究访问中,52%(575 人)的患者报告出现疲劳,其中 9% 的患者在病程早期报告出现中度至重度疲劳。多个量表的较高评分与疲劳风险的增加有显著相关性,但大多数相关性较弱。显著相关的量表包括快速眼动睡眠行为障碍问卷(OR:1.09,95% CI:1.06-1.11)、老年抑郁量表(OR:1.07,95% CI:1.03-1.11)、状态-特质焦虑量表(OR:1.01,95% CI:1.00-1.02)、SCOPA-自主神经功能障碍(OR:1.结论:超过一半的患者在基线时报告有疲劳症状,这表明疲劳在帕金森病早期的发病率很高。与其他 NMS 的关联性较弱,这突出表明有必要对患者进行全面筛查并采取有针对性的干预措施,因为治疗一种 NMS 可能无法有效缓解其他 NMS。
{"title":"Exploring the layers of fatigue in Parkinson’s Disease: A comprehensive analysis of its prevalence and contributing factors","authors":"Filipe Sarmento ,&nbsp;Griffin Lamp ,&nbsp;Venkat Srikar Lavu ,&nbsp;Achyutha S. Madamangalam ,&nbsp;Jagan Mohan Reddy Dwarampudi ,&nbsp;Qingqi Yuan ,&nbsp;Alfonso Enrique Martinez-Nunez ,&nbsp;Julia Choi ,&nbsp;Kara A. Johnson ,&nbsp;Coralie de Hemptinne ,&nbsp;Joshua K. Wong","doi":"10.1016/j.prdoa.2024.100288","DOIUrl":"10.1016/j.prdoa.2024.100288","url":null,"abstract":"<div><h3>Background</h3><div>Fatigue is a prevalent yet under-recognized non-motor symptom (NMS) of Parkinson’s disease (PD), significantly impacting patients’ quality of life. Despite its clinical importance, the relationship between fatigue and other motor and non-motor symptoms remains poorly understood. Its frequent co-occurrence with other NMS further complicates both diagnosis and management, often leading to underdiagnosis and suboptimal treatment. This gap in understanding is largely due to the limited exploration of fatigue in PD.</div></div><div><h3>Objective</h3><div>This study aimed to evaluate the prevalence of fatigue at baseline and up to 10 years after symptom onset in a large, well-characterized PD cohort (PPMI) and to explore its associations with other non-motor symptoms (NMS). By providing insights into the prevalence and correlations of fatigue, our goal is to highlight the need for early identification and management, guiding future research efforts.</div></div><div><h3>Methods</h3><div> <!-->We conducted a retrospective study using the PPMI database. Fatigue was assessed using item 1.13 of the Movement Disorders Society Unified Parkinson’s Disease Rating Scale. Logistic regression was used to analyze the impact of different variables on fatigue, while point-biserial correlation analysis gauged the relationship between continuous variables and fatigue.</div></div><div><h3>Results</h3><div>At baseline study visit, 52% (575) of patients reported experiencing fatigue, with 9% reporting moderate to severe fatigue early in the disease course. Higher scores on several scales were significantly associated with an increased risk of fatigue, though most associations were weak. Significant associations included the REM Sleep Behavioral Disorder Questionnaire (OR: 1.09, 95% CI: 1.06–1.11), Geriatric Depression Scale (OR: 1.07, 95% CI: 1.03–1.11), State-Trait Anxiety Inventory (OR: 1.01, 95% CI: 1.00–1.02), SCOPA-Autonomic Dysfunction (OR: 1.05, 95% CI: 1.03–1.06), Epworth Sleepiness Scale (OR: 1.06, 95% CI: 1.04–1.08), and Apathy (OR: 2.90, 95% CI: 2.4–3.5).</div></div><div><h3>Conclusion</h3><div>Over half of patients reported fatigue at baseline, underscoring its significant prevalence early in PD. The predominantly weak associations with other NMS highlight the necessity for comprehensive patient screening and targeted interventions, as addressing one NMS may not effectively alleviate others.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"11 ","pages":"Article 100288"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142705956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Japanese longitudinal biomarker study in progressive supranuclear palsy and corticobasal degeneration: Clinical features of the first registered patients and short-term follow-up analysis 日本进行性核上性麻痹和皮质基底变性的纵向生物标志物研究:首批登记患者的临床特征和短期随访分析
IF 1.9 Q3 CLINICAL NEUROLOGY Pub Date : 2024-01-01 DOI: 10.1016/j.prdoa.2024.100279
Hiroshi Takigawa , Ritsuko Hanajima , Ikuko Aiba , Takayoshi Shimohata , Takahiko Tokuda , Mitsuya Morita , Osamu Onodera , Shigeo Murayama , Kazuko Hasegawa , Aya M. Tokumaru , Hisanori Kowa , Masato Kanazawa , Tameto Naoi , Kenji Nakashima , Takeshi Ikeuchi , JALPAC study group

Introduction

Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) manifest with variable clinical features. We initiated a multicenter prospective registry study—the Japanese Longitudinal Biomarker Study in PSP and CBD—in November 2014 at 45 Japanese institutions to collect clinical information and biological samples to elucidate the natural courses and diagnostic biomarkers of PSP/CBD.

Methods

Initial symptoms, clinical features, and scores (Progressive Supranuclear Palsy Rating Scale [PSPRS], Barthel Index, Mini-Mental State Examination, and Frontal Assessment Battery) of patients clinically diagnosed with PSP/corticobasal syndrome (CBS) at the first registration were analyzed. PSPRS score progression in the initial 8 years and predictive factors were examined.

Results

As of October 2022, first registration had been conducted for 349 patients—57 with probable/possible Richardson’s syndrome (RS), 133 with possible CBS, 41 with overlapping CBS and PSP criteria (RS/CBS group), 20 with PSP subtypes other than RS, and 98 who did not fulfill the PSP or CBS criteria. Among the RS, CBS, and RS/CBS groups, the RS group exhibited the best scores. Initial symptoms of personality change and asymmetric onset were correlated with the total PSPRS score. The average PSPRS score increment by the second registration (n = 116 patients) was 11.8 in all three groups, and progression was correlated with cognitive dysfunction. Seventy patients died during the study period. The 5-year survival rate from onset was approximately 90 %.

Conclusion

There were fewer severe clinical features in the RS group than in the CBS group. Cognitive dysfunction may be important in predicting clinical severity and disease progression.
导言:进行性核上性麻痹(PSP)和皮质基底变性(CBD)表现出不同的临床特征。我们于 2014 年 11 月在日本 45 家机构启动了一项多中心前瞻性登记研究--日本 PSP 和 CBD 纵向生物标志物研究,收集临床信息和生物样本,以阐明 PSP/CBD 的自然病程和诊断生物标志物。方法分析首次登记时临床诊断为PSP/皮质基底综合征(CBS)患者的初始症状、临床特征和评分(进行性核上麻痹评分量表[PSPRS]、巴特尔指数、迷你精神状态检查和额叶评估电池)。结果 截至2022年10月,已对349名患者进行了首次登记,其中57人可能患有理查森综合征(RS),133人可能患有CBS,41人CBS和PSP标准重叠(RS/CBS组),20人患有RS以外的PSP亚型,98人不符合PSP或CBS标准。在 RS 组、CBS 组和 RS/CBS 组中,RS 组的得分最高。人格改变和不对称发病的初始症状与 PSPRS 总分相关。所有三组患者在第二次登记时(n = 116 名患者)的 PSPRS 平均增量为 11.8 分,其进展与认知功能障碍相关。研究期间有 70 名患者死亡。结论 RS 组的严重临床特征少于 CBS 组。认知功能障碍可能是预测临床严重程度和疾病进展的重要依据。
{"title":"Japanese longitudinal biomarker study in progressive supranuclear palsy and corticobasal degeneration: Clinical features of the first registered patients and short-term follow-up analysis","authors":"Hiroshi Takigawa ,&nbsp;Ritsuko Hanajima ,&nbsp;Ikuko Aiba ,&nbsp;Takayoshi Shimohata ,&nbsp;Takahiko Tokuda ,&nbsp;Mitsuya Morita ,&nbsp;Osamu Onodera ,&nbsp;Shigeo Murayama ,&nbsp;Kazuko Hasegawa ,&nbsp;Aya M. Tokumaru ,&nbsp;Hisanori Kowa ,&nbsp;Masato Kanazawa ,&nbsp;Tameto Naoi ,&nbsp;Kenji Nakashima ,&nbsp;Takeshi Ikeuchi ,&nbsp;JALPAC study group","doi":"10.1016/j.prdoa.2024.100279","DOIUrl":"10.1016/j.prdoa.2024.100279","url":null,"abstract":"<div><h3>Introduction</h3><div>Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) manifest with variable clinical features. We initiated a multicenter prospective registry study—the Japanese Longitudinal Biomarker Study in PSP and CBD—in November 2014 at 45 Japanese institutions to collect clinical information and biological samples to elucidate the natural courses and diagnostic biomarkers of PSP/CBD.</div></div><div><h3>Methods</h3><div>Initial symptoms, clinical features, and scores (Progressive Supranuclear Palsy Rating Scale [PSPRS], Barthel Index, Mini-Mental State Examination, and Frontal Assessment Battery) of patients clinically diagnosed with PSP/corticobasal syndrome (CBS) at the first registration were analyzed. PSPRS score progression in the initial 8 years and predictive factors were examined.</div></div><div><h3>Results</h3><div>As of October 2022, first registration had been conducted for 349 patients—57 with probable/possible Richardson’s syndrome (RS), 133 with possible CBS, 41 with overlapping CBS and PSP criteria (RS/CBS group), 20 with PSP subtypes other than RS, and 98 who did not fulfill the PSP or CBS criteria. Among the RS, CBS, and RS/CBS groups, the RS group exhibited the best scores. Initial symptoms of personality change and asymmetric onset were correlated with the total PSPRS score. The average PSPRS score increment by the second registration (n = 116 patients) was 11.8 in all three groups, and progression was correlated with cognitive dysfunction. Seventy patients died during the study period. The 5-year survival rate from onset was approximately 90 %.</div></div><div><h3>Conclusion</h3><div>There were fewer severe clinical features in the RS group than in the CBS group. Cognitive dysfunction may be important in predicting clinical severity and disease progression.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"11 ","pages":"Article 100279"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142560754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dystonia: A novel sign of the Smith-Magenis syndrome – A three-case report 肌张力障碍:史密斯-马盖尼综合征的一种新征兆--三例病例报告
IF 1.9 Q3 CLINICAL NEUROLOGY Pub Date : 2024-01-01 DOI: 10.1016/j.prdoa.2024.100267
Lukáš Kunc , Petra Havránková , Matěj Škorvánek , Iva Příhodová , Kamila Poláková , Lenka Nosková , Markéta Tesařová , Tomáš Honzík , Michael Zech , Robert Jech
{"title":"Dystonia: A novel sign of the Smith-Magenis syndrome – A three-case report","authors":"Lukáš Kunc ,&nbsp;Petra Havránková ,&nbsp;Matěj Škorvánek ,&nbsp;Iva Příhodová ,&nbsp;Kamila Poláková ,&nbsp;Lenka Nosková ,&nbsp;Markéta Tesařová ,&nbsp;Tomáš Honzík ,&nbsp;Michael Zech ,&nbsp;Robert Jech","doi":"10.1016/j.prdoa.2024.100267","DOIUrl":"10.1016/j.prdoa.2024.100267","url":null,"abstract":"","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"11 ","pages":"Article 100267"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590112524000380/pdfft?md5=bfde844c2a7a4800a64e5a7faa6d7c55&pid=1-s2.0-S2590112524000380-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141963827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical Parkinsonism Related Disorders
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1